Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

about

Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: Not Yet.Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels.

P2860

Q50102117-D07FA95B-F489-4F36-966D-882722BBCF57 Q55427313-421C4FC4-F56E-465B-AEFC-06B43EA1E6EF

P2860

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

Item

http://www.wikidata.org/entity/Q38817406

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

@en

type

Item

label

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

@en

prefLabel

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

@en

P1476

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer

@en

P2093

Jan-Erik Damber

http://www.w3.org/2001/XMLSchema#string

Mats Lambe

http://www.w3.org/2001/XMLSchema#string

Pär Stattin

http://www.w3.org/2001/XMLSchema#string

Yasin Folkvaljon

http://www.w3.org/2001/XMLSchema#string

P2860

Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men

Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels

Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Evaluation of data quality in the National Prostate Cancer Register of Sweden.

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Trends in androgen prescribing in the United States, 2001 to 2011.

Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0.

EMAS position statement: Testosterone replacement therapy in the aging male‏.

Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis.

P304

1430-1436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2016.69.5304

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stacy Loeb

Joseph P Alukal

P577

2017-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28447913

http://www.w3.org/2001/XMLSchema#string

P932

5455459

http://www.w3.org/2001/XMLSchema#string

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

about

P2860

P2860

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932